Audentes Therapeutics Aktie
WKN DE: A2ANZC / ISIN: US05070R1041
13.05.2024 13:17:35
|
Boundless Bio, Inc. Q1 Loss Climbs
(RTTNews) - Boundless Bio, Inc. (BOLD) revealed Loss for its first quarter that increased from last year
The company's bottom line totaled -$15.430 million, or -$12.27 per share. This compares with -$11.719 million, or -$9.91 per share, in last year's first quarter.
Boundless Bio, Inc. earnings at a glance (GAAP) :
-Earnings (Q1): -$15.430 Mln. vs. -$11.719 Mln. last year. -EPS (Q1): -$12.27 vs. -$9.91 last year.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Audentes Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |